Mopping up Around the Cell

What happens when proteins can't find their partners?

Cells have a lot of garbage disposal issues. There are lysosomes to digest large things like viruses, proteasomes to dispose of individual proteins, and lots of surveillance mechanisms to check that things are going as they should- that proteins coming off the ribosome are complete, that mRNAs are being spliced, that mitochondria are charged up as they should be, that the endoplasmic reticulum is making, folding, and secreting proteins as it should be, among many others. One basic problem that arises when cells have a lot of proteins that assemble and cooperate in the form of complexes, is that some of those subunits may be present in excess, or not join their intended complexes for other reasons such as misfolding. This can have very bad effects. Most protein binding makes use of hydrophobic surfaces, and having these floating around freely can lead to indiscriminate binding / agglomeration, like amyloid plaque formation, and cell death.

Bacteria have one partial solution, which is to encode proteins that are destined to the same complex from the same mRNA, made from what is called an "operon" of genes, like a train with successive gene-carriages. Each multi-protein-encoding message from such an operon is thus necessarily equally abundant, and, assuming simiar ribosomal rates of protein synthesis, the proteins should also be produced in equal quantities, providing at least one method to balance their abundance in the cell. But there are many other issues- proteins may have different life-spans, or different ribosomal production rates, or assembly into the complex may be slow and difficult, so bacteria still are not out of the woods. Eukaryotes do not use operons anyhow, so our more-finely regulated gene control mechanisms are called on to properly equalize (or adjust for) the ultimate subunit concentrations. 

But when all this fails, and there is more of some complex subunit than needed, what happens then? When experimenters over-produce some complex component in cells, it is typically short-lived. And if they impair its production, the rest of the complex tends to be short-lived. This implies mechanisms in the cell to dispose of incomplete complexes and their components. It turns out that there are some specific chaperone proteins that detect such orphan subunits, and tag them to be destroyed. Several prominent complexes, such as ribosomes and proteasomes, even have specifically dedicated mop-up chaperones. A recent paper described a chaperone protein dedicated to mopping up the excess or misfolded subunits of another large and abundant complex - the chaperonin complex. That makes this protein, ZNRD2, a sort of metachaperone.

Some structural (though not dynamic) views of the CCT complex. A shows top and side views, respectively. C shows a layout of how the equator of the complex looks, as coded by each of the subunits. At the ring-ring interfaces are the ATP binding sites (d). And lastly (e) a cut-away view of the inside show where substrate proteins are enclosed and encouraged to fold correctly.

The chaperonin complex, (also called CCT), is a large, hollow sphere that actively helps other proteins to fold correctly. The structural proteins actin and tubulin are the most prominent targets that need this help. When first synthesized, they are bound by adapters that ferry them to the chaperonin complex, which lifts its lid to allow the protein in. Then, ATP is used to induce dramatic cycling of the chaperonin structure, shifting from an internal hydrophobic structure to a more hydrophilic one. This allows the unfolded protein to alternately splay open over the hydrophobic surface, and then fold in piece-wise fashion, for as long as it takes till the barrel detects that it is fully folded and no longer sticking to the hydrophobic internal surfaces.

In the current work, the researchers drove the expression of several individual CCT subunits in cell lysates. Then they sent the products into a mass spectrometer to find out what was sticking to these "orphan" proteins. They found two major associated proteins, HERC2, and ZNRD2. HERC2 is known as a ubiquitin ligase, which is one of a large family of enzymes that tag proteins with ubiquitin, targeting them for disposal. But ZNRD2 was totally uncharacterized, known only as an auto-antigen reacted to by some people with Sjogren's syndrome or scleroderma. The question then was .. does HERC2 directly sense the presence of free-floating CCT subunits, or does it need a helper to do so, such as perhaps ZNRD2?

"... a sizable population of multiple CCT subunits are orphaned even under normal conditions, and the degradation of a subset of these can be stimulated by HERC2."

The researchers showed that deleting HERC2 strongly impaired the cleanup of most orphan CCT subunits. It is evident, however, that there are other chaperones not covered in this work that help clean up some of the other CCT subunits. Then they found that HERC2 interaction with the CCT proteins was dependent on ZNRD2, but that the reverse was not the case- ZNRD2 binds CCT subunits in any case. This, and other experiments, including mapping the location within the HERC2 protein that binds ZNRD2, showed that ZNRD2 is the adapter that does the detailed detection of orphaned CCT subunits. At only 199 amino acids, there is not much to it, and searches for domain signatures do not yield much. Its name reflects a structure that uses zinc ions for stabilization, but much of the protein is also disordered. It is notable for a high proportion of hydrophobic amino acids (alanine, leucine) and lots of prolines (15), which would contribute to a disordered structure. 

Thankfully, with the advent of AI and alpha-fold, these researchers could also investigate and model how ZNRD2 interacts with both the HERC2 ubiquitin ligase and with one of the CCT subunits, CCT4- all without doing any laborious structure determinations.

AI-calculated structures of the complex of the ubiquitin ligase HERC2 with the adaptor ZNRD2 and the target subunit CCT4. At right, the hydrophobic residues of CCT4 are colored yellow, showing that the ZNRD2 orphan subunit detector and adaptor binds to a hydrophobic pocket which would otherwise be completely buried with the full CCT structure. The interacting domain of HERC4 in green is termed a 7-bladed beta propeller.

"In the fully assembled CCT double ring, all potential ZNRD2 interaction sites are completely buried because they form the interface between the two individual rings."

 

They found that ZNRD2 binds to a hydrophobic pocket of CCT4, a pocket that is otherwise buried in the fully assembled CCT. This patch would also be exposed on partially assembled CCT complexes, indicating that this interaction is not only relevant for mopping up the individual subunit, but for several kinds of incomplete assembly of the entire complex, perhaps explaining why other subunits are also mopped up by this system. 

This kind of work is a good example of normal science. A gene about which nothing was previously known (ZNDR2) is now given a function in the cell, and a process circumstantially known to exist is fleshed out with actors and structures that explain it. Of the ~20,000 human protein-coding genes, roughly ten percent still have no annotation, and many more have only tenuous annotation, perhaps only drawn from structural analogy, not direct study. So there is a great deal more work needed to evaluate our parts list, even on the most basic level, even before getting into the complexities of how these proteins act and interact in tissues and pathways. 

• What are the hippos thinking?
• Vodka is apparently a thing.
• Just how low is this grift going?
• Who gets to reproduce, and who gets killed? Population control at the heart of the Jewish state.
• Genetics and parenting.
• No, absolutely not.. this can not be true.

Nominee for Most Amazing Protein: RAD51

On the repair and resurrection of DNA, which gets a lot of help from a family of proteins including RAD51, DMC1, and RecA.

Proteins do all sorts of amazing things, from composing pores that can select a single kind of ion- even just a proton- to allow across a membrane, to massive polymerizing enzymes that synthesize other proteins, DNA, and RNA. There is really no end to it. But one of the most amazing, even incredible, things that happens in a cell is the hunt for DNA homology. Even over a genome of billions of base pairs, it is possible for one DNA segment to find the single other DNA segment that matches it. This hunt is executed for several reasons. One is to line up the homologous chromosomes at meiosis, and carry out the genetic cross-overs between them (when they are lined up precisely) that help scramble our genetic lineages for optimal mix-and-matching during reproduction. Another is for DNA repair, which is best done with a good copy for reference, especially when a full double-strand break has happened. Just this week, a fascinating article showed that memories in our brains depend in some weird way on DNA breaks occurring in neurons, some of which then use the homologous repair process, including homology search, to patch things up.

The protein that facilitates this DNA homology search is deeply conserved in evolution. It is called RecA in bacteria, radA and radB in archaea, and the RAD51 family in eukaryotes. Naturally, the eukaryotic family is most closely related to the archaeal versions (RAD51 and DMC1 evolving from radA, and a series of other, and poorly understood family members, from radB). In this post, I will mostly just call them all RAD51, unless I am referring to DMC1 specifically. The name comes from genetic screens for radiation-sensitive mutants in human and other eukaryotes, since RAD51 plays a crucial role in DNA repair, as noted above. RAD51 is not a huge protein, but it is an ATPase. It binds to itself, forming linear filaments with ATP at the junction points between units. It binds to a single strand of DNA, which is going to be what does the hunting. And it binds, in a complicated way, to another double-stranded DNA, which it helps to open briefly to allow its quality as a target to be evaluated. 

This diagram describes the repair of double strand breaks (DSB) in DNA. First the ends are covered with a bunch of proteins that signal far and wide that something terrible has happened- the cell cycle has to stop.. fire engines need to be called. One of these proteins is RPA, which simply binds all over single-stranded DNA and protects it. Then the RAD51 protein comes in, displaces RPA, and begins the homology search process. The second DNA shown, in dark black, doesn't just happen, but is hunted for high and low throughout the nucleus to find the exact homolog of the broken end. When that exact match is found, the repair process can proceed, with continued DNA synthesis through the lesion, and resolution of the newly repaired double strands, either to copy up the homolog version, or exchange versions (GC, for gene conversion). 

This diagram shows how the notorious (when mutated) oncogene BRCA2 (in green) works. It binds RAD51 (in blue) and brings it, chain-gang style, to the breakpoints of DNA damage to speed up and specify repair.

There have been several structural studies by this point that clarify how RAD51 does its thing. ATP is simply required to form filaments on single-stranded DNA. When a match has been found and RAD51 is no longer needed, ATP is cleaved, and RAD51 falls off, back to reserve status. The magic starts with how RAD51 binds the single stranded DNA. One RAD51 binds for every ~3 bases in the DNA, and the it binds the phosphate backbone, so that the bases are nicely exposed in front, and all stretched out, ready to hunt for matching DNA.

A series of RAD51 molecules (in this case, RecA from bacteria) bound sequentially to single-stranded DNA (red). Note the ATP homolog chemicals in yellow, positioned between each protein unit. One can see that the DNA is stretched out a bit and the bases point outwards.

A closeup view of one of the RAD51 units from above, showing how the bases of the DNA (yellow) are splayed out into the medium, ready to find their partners. They are arranged in orientations similar to how they sit in normal (B-form) DNA, further enhancing their ability to find partners.

The second, and more mysterious part of the operation is how RAD51 scans double-stranded DNA throughout the genome. It has binding sites for double-stranded DNA, away from the single-stranded DNA, and then it also has a little finger that splits open the double-stranded DNA, encouraging separation and allowing one strand to face up to the single stranded DNA that is held firmly by the RAD51 polymer. The transient search happens in eight-base increments, with tighter capture of the double-strand DNA happening when nine bases are matched, and committment to recombination or repair happening when a match of fifteen bases is found.  

These structures show an intermediate where a double-stranded DNA (ends in teal and lavender, and separated DNA segments in green and red) has been captured, making a twelve base match with the stable single-stranded DNA (brown). Note how the double-stranded DNA ends are held by outside portions of the RAD51 protein. Closeup on the right shows the dangling, non-paired DNA strand in red, and the newly matched duplex DNA with green-brown colored base interactions.

These structures can only give a hint of what is going on, since the whole process relies so clearly on the brownian motion that allows super-rapid diffusion of the stablized single-strand DNA+RAD51 over the genome, which it scans efficiently in one-dimensional fashion, despite all the chromatin and other proteins parked all over the place. And while the structures provide insight into how the process happens, it remains incredible that this search can happen, on what is clearly a quite reliable basis, day and day out, as our genomes get hit by whatever the environment throws at us.

"Unfortunately, most RAD51 and RAD51 paralog point mutations that have been clinically identified are classified as variants of unknown significance (VUSs). Future studies to reclassify these RAD51 gene family VUSs as pathogenic or benign are desperately needed, as many of these genes are now included on hereditary breast and ovarian cancer screening panels. Reclassification of HR-deficient VUSs would enable these patients to benefit from therapies that specifically target HR deficiency, as do poly(ADP)-ribose polymerase (PARP) inhibitors in BRCA1/2-deficient cells."

Lastly, one paper made the point that clinicians need better understanding of the various mutations that can affect RAD51 itself. Genetic testing now is able to find all of our mutations, but we don't always know what each mutation is capable of doing. Thus deeper studies of RAD51 will have beneficial effects on clinical diagnosis, when particular mutations can be assigned as disease-causing, thus justifying specific therapies that would otherwise not be attempted.

• Let's make taxes public.
• A plea for less sugar.

Renewable Power in Africa

Prospects for growth in electricity access and in clean energy.

Africa is an enormous continent, notoriously larger than China, the US, and Europe combined. Its population is also large- as large as that of India, at about 1.4 billion people. This population is growing rapidly, while its social and economic systems are developing more slowly. But as we know, the main ingredient of an advanced economy is power, which as traditionally been drawn from fossil fuels. Advanced economies are in the painful and reluctant process of transitioning away from fossil fuels. We can do a lot to help Africa to leapfrog this history by front-loading renewable energy.

There was a recent paper about the hydropower prospects in Africa. It notes that there are many projects on the drawing board, with many undammed rivers on the continent. But as we have learned in the US, the implications of river damming are quite destructive and wide-spread. For example fish ladders simply do not work- not at the scale needed to keep fish populations (and fisheries) healthy. Then there are problems of siltation, water temperature, erratic flows, and population displacement. There is a movement in the US to remove dams wherever possible, to free ecosystems back to a functional state. 

"More than 300 hydropower plants, corresponding to an additional 100-GW power capacity, are under consideration across the continent."

The article made the basic point that, given the state of other renewable power sources, and the prospect of lower water levels and droughts due to climate change, that roughly half of the planned hydropower projects they know of are economically inviable, even putting aside environmental considerations. 

This leads to the question of what to do instead? Maybe the answer is microgrids. In the developed world, it is increasingly common for people to take control of their own electricity production through the use of solar power. But at a single house level, power inputs and consumption are both erratic and require a lot of storage capacity to furnish a reliable system. The typical system is highly reliant on the larger grid to manage this intermittency. Microgrids occupy a middle range between grid-scale power, which is subject to problems of centralized political and social development, and the individual house, where the expense of managing fully independent electrical supply is highest.

The current grid in Africa, colored for >66 kV (dark blue) and the rest light blue. Note the patchy regional distribution, with lots of underserved areas. The US has a much denser grid. 

A map that suggests likely locations for smaller microgrids in Africa.

These maps note that there are many underserved areas in Africa- some concentrated urban areas, and a great spread of rural areas. Electrification is well-advanced in South Africa and the heart of West Africa. But there are many rural areas that would be better served by microgrids of various scales. Microgrids can be altered over time and integrated into larger systems. Their production and storage capacities are both beneficial for larger grid stability and scalability. Africa is, naturally, positioned ideally for solar power, and the Sahara is a natural location for massive power installations, to serve both Europe, the Middle East, and Africa.

A proposal to run a super-grid around much of Africa, to harness supplies from the Sahara, among other sources.

One of the main characteristics of renewable power is that it has high up-front costs. The fuel is free, and clean. But the mechanisms to capture and store it are expensive. Thus if we want to encourage a more rapid transition to sustainable power systems in Africa, we would help pay for the up front costs, sharing capital investment in the interests of everyone, both here and there. Africa is currently a big exporter of oil and gas. As other regions transition away from those fuels, it is imperative that this production not be redirected and propped up by further Western investment, but rather replaced with better energy sources.

• Advanced nuclear power is not going to cut it.
• The heat pump song.
• Treason, again.
• On silence and isolation.
• Housing prices should not always go up.
• Medicare disadvantage.

Getting Cancer Cells to Shoot Themselves

New chemicals that make novel linkages among cellular components can be powerful drugs.

One theme that has become common in molecular biology over the years is the prevalence of proteins whose only job is to bring other proteins together. Many proteins lack any of the usual jazzy functions, like catalytic enzyme, or ion channel, or signaling kinase, but just serve as "conveners", bringing other proteins together. Typically they are regulated in some way, by phosphorylation, expression, or localization, and some of these proteins serve as key "scaffolds" for the activation of some process, like G-protein activation, or cell cycle control, or cell growth. 

Well, the drug industry has caught on, and is starting to think about chemicals that can do similar things, resulting in occasionally powerful results. Conventional drug design has aimed to bind to whatever protein is responsible for some ill, and inhibit it. Such as an oncogene, or an over-active component of the immune system. This has led to many great drugs, but has significant limitations. The chemical has to bind not just anywhere on the target, but at the particular spot (the active site) that is its business end, where its action happens. And it has to bind really well, since binding and inhibiting only half the target proteins in a cell (or the body) will typically only have a modest effect. These requirements are quite stringent and result in many protein targets being deemed difficult to drug, or "undruggable".

A paradigm for a new kind of chemical drug, which links two functions, is the PROTAC class, which combines binding with a target on one end, with another end that binds to the cell's protein destruction machinery, thereby not just inhibiting the target, but destroying it. A new paper describes an even more nuclear option along this line of drug development, linking an oncogene with a second part that activates the cellular suicide machinery. One can imagine that this approach can have far more dramatic effects.

These researchers synthesize and demonstrate a chemical that binds on one end the oncogene BCL6, mutations of which can cause B cell lymphoma. This gene is a transcription repressor, and orchestrates the development of particular immunologic T cells called T follicular helper cells. One of its roles is to prevent the suicide of these cells when an antigen is present, which is when the cells are most needed. If over-expressed in cancer, these cells think they really need to protect the body and proliferate wildly.

The other end of this chemical, called TCIP1, binds to BRD4, which is another transcription regulator, but this one activates the cell suicide genes, instead of turning them off. Both ends of this molecule were based on previously known structures. The innovation was solely in linking them together. I should say parenthetically that BRD4 is itself recognized as an oncogene, as it can promote cell growth and prevent cell suicide in many settings. So it has ambivalent roles, (inviting a lot of vague writing), and it is somewhat curious that these researchers focused on BRD4 as an apoptosis driver.

"TCIP1 kills diffuse large B cell lymphoma cell lines, including chemotherapy-resistant, TP53-mutant lines, at EC50 of 1–10 nM in 72 h" 

Here EC50 means the effective concentration where the effect is 50% of maximal. This value of 1.3 nano molar is a very low concentration for a drug, meaning it is highly effective. TP53 is another cancer-driving mutation, common in treatment-resistant cancers. The drug has a characteristic and curious dosage behavior, as its effect decreases at higher concentrations. This is because each individual end of the molecule starts to bind and saturate targets independently, reducing the rate of linkage between the two target proteins, and thus the intended effect.

Chemical structure of TCIP1. The left side binds to BRD4, a regulator of cell suicide, while the right side binds to BCL6, an oncogene.

The authors did numerous controls with related chemicals, and tracked genes that were targeted by the novel chemical, all to show that the dramatic effects they were seeing were specifically caused by the linkage of the two chemical functions. Indeed, BCL6 represses its own transcription in the natural course of affairs, and the new drug reverses this behavior as well, inducing more of its own synthesis, which now potentiates the drug's lethal effect. While the authors did not show effectiveness in animals, they did show that TCIP1 is not toxic in mice. Neither did they show that TCIP1 is orally available, but administered it by injection. But even by this mode, it would, if effective, be a very exciting therapy. Not surprisingly, the authors report a long series of biotech industry ties (rooted at Stanford) and indicate that this technology is under license for drug development.

This approach is highly promising, and a significant advance in the field. It should allow increased flexibility in targeting all kinds of proteins that may or not cause disease, but are specific to or over-expressed in disease states, in order to address those diseases. It will allow increased flexibility in targeting apoptosis (cell suicide) pathways through numerous entry points, to have the same ultimate (and highly effective) therapeutic endpoint. It allows drugs to work at low concentrations, not needing to fully occupy or inhibit their targets. Many possible areas of therapy can be envisioned, but one is aging. By targeting and killing senescent cells, which are notorious for promoting aging, significant increases in lifespan and health are conceivable. 

• Biden is doing an excellent job.
• Annals of mental decline.
• Maybe it is an anti-addiction drug.
• One gene that really did the trick.
• A winning issue.
• It is hard to say yet whether nuclear power is a climate solution, or an expensive distraction.

Ions: A Family Saga

The human genome encodes hundreds of proteins that ferry ions across membranes. How did they get here? How do they work?

As macroscopic beings, we generally think we are composed of tissues like bones, skin, hair, organs. But this modest apparent complexity sits atop a much greater and deeper molecular diversity- of molecules encoded from our genes, and of the chemistry of life. Management of cellular biochemistry requires strict and dynamic control of all its constituents- the many ions and myriad organic molecules that we rely on for energy, defense, and growth. One avenue is careful control across the cellular membrane, setting up persistent differences between inside and outside that define the living cell- one may say life itself. Typical cells have higher levels of potassium inside, and higher levels of sodium and chloride outside, for example. Calcium, for another example, is used commonly for signaling, and is kept at low concentrations in the cytoplasm, while being concentrated in some organelles (such as the sarcoplasmic reticulum in muscle cells) and outside. 

All this is done by a fleet of ion channels, pumps, and other solute carriers, encoded in the genome. We have genes for about 1,555 molecule transporters. Out of a genome of about 20,000 genes, this represents a huge concentration(!) of resources. One family alone, the solute carrier (SLC) family, has 440 members. Many of these are passive channels, which just let their selected cargo through. But many are also co-transporters, which harness the transport of one ion with that of another which may have an actively pumped gradient across the membrane and thus provide an indirect energy source for transfer of the first ion. The SLC family includes channels for glucose, amino acids, neurotransmitters, chloride, cotransport (or anti-transport) of sodium with glucose, calcium, neurotransmitters, hydrogen, and phosphate. Also, metals like zinc, iron, copper, magnesium, molybdate, nucleotides, steroids, drugs/toxins, cholesterol, bile, folate, fatty acids, peptides, sulfate, carbonate, and many others. 

It is clear that these proteins did not just appear out of nowhere. The "intelligent" design people recognize that much, that complex structures, which these are, must have some antecedent process of origination- some explanation, in short. Biologists call the SLC proteins a family because they share clear sequence similarity, which derives, by evolutionary theory, and by the observed diversification of genes and the organisms encoding them over time, from duplication and diversification. This, sadly, is where the "intelligent" design proponents part ways in logic, maintaining perhaps the most pathetic (and pedantic) bit of hooey ever devised by the dogmatic believer: "specified information", which apparently forbids the replication of information.

However, information replicates all the time, thanks to copious inputs of energy from the sun, and the advent of life, which can transform energy into profusions of reproduced/replicated organisms, including replication of all their constituent parts. For our purposes, one side effect of all this replication is error, which can cause unintended replication/duplication of individual genes, which can then diverge in function to provide the species with new vistas of, in this case, ionic regulation. In yeast cells, there are maybe a hundred SLC genes, and fewer in bacteria. So it is apparent that the road to where we are has been a very long one, taking billions of years. Gene duplication is a rare event, and each new birth a painful, experimental project. But a family with so many members shows the fecundity of life, and the critical (that is, naturally selected) importance of these transporters in their diverse roles throughout the body.

A few of the relatives in the SLC26A family, given in one-letter protein sequence from small sections of the much larger protein, around the core ion binding site. You can see that they are, in this alignment, very similar, clearly being in the same family. You can also see that SLC26A9 has "V" in a position in alpha helix 10, which in all other members is a quite basic amino acid like lysine ("K") or arginine ("R"). The authors argue that this difference is one key to the functional differences between it and SLC26A6.

A recent paper showed structures for two SLC family members, which each transport chloride ion, but differ in that one exchanges chloride for bicarbonate, while the other allows chloride through without a matched exchange (though see here). SLC26A9 is expressed in the gut and lung, and apparently helps manage fluid levels by allowing chloride permeability. It is of interest to those with cystic fibrosis, because the gene responsible for that disorder, CFTR, is another transporter, (of the ABC family), and plays a major role doing a similar thing in the same places- exchanging chloride and bicarbonate, which helps manage the pH and fluidity of our mucus in the lung and other organs. SLC26A9, having a related role and location, might be able to fill some of the gap if drugs could be found to increase its expression or activity.

SLC26A6 is expressed in the kidney, pancreas, and gut, and in addition to exchanging bicarbonate for chloride, can also exchange oxalate, which prevents kidney stones. Very little, really, is known about how all these ion transporters are expressed and regulated, what differentiates them, how they relate to each other, and what prompted their divergence through evolution. We are really just in the identification and gross characterization stage. The new paper focuses on the structural mechanisms that differentiate these two particular SLC family members.

Structure of two SLC transporters, each dimeric, and superimposed. The upper parts are set in the membrane, with the lower parts in the cytoplasm. The upper parts combine two domains for each monomer, the "core" and "gate" domains. The channel for the anion threads within the center of each upper part, between these two domains. Note how structurally similar the two family members are, one in green+gray, the other in red+blue.

Schemes of how SLC26A6 works. The gate domain (purple) is stable, while the core domain (green) rocks to provide access from the ion binding site to either outside or inside the cell.

Like any proper ion channel, SLC26A6 sits in the membrane and provides a place for its ion to transiently bind (for careful selection of the right kind of ion) and then to go through. There is a central binding site that is lined specially with a few semi-positively charged amino acids like asparagine (N), glutamine (Q) and arginine (R), which provide an attactive electronic environment for anions like Cl-. The authors describe a probable mechanism of action, (above), whereby the core domain rocks up and down to allow the ion to pass through, after being very sensitively bound and verified. This rocking is not driven by ATP or other outside power, but just by brownian motion, as gated by the ion binding and unbinding steps.

Drilling a little closer into the target ion binding site of SLC26A6. On right is shown Cl- in green, center, with a few of the amino acids that coordinate its specific, but transient, binding in the core domain pocket. 

They draw contrasts between these very closely related channels, in that the binding pocket is deeper and narrower in SLC26A9, allowing the smaller Cl- to bind while not allowing HCO3- to bind as well. There are also numerous differences in the structure of the core protein around the channel that they argue allow coupling of HCO3- transport (to Cl- transport in the other direction) in SLC26A6, while SLC26A9 is uncoupled. One presumes that the form of the ion site can be subtly altered at each end of the rocking motion, so that the preferred ion is bound at each end of the cycle.

While all this work is splitting fine hairs, these are hairs presented to us by evolution. It is evolution that duplicated the precursors to these genes, then retained them while each, over time, developed its fine-tuned differences, including different activities and distinct tissue expression. Indeed, the fully competent, bicarbonate exchanging, SLC26A6 is far more widely expressed, suggesting that SLC26A9 has a more specialized role in the body. To reiterate a point made many times before- having the whole human genome sequenced, or even having atomic structures of all of its encoded proteins, is merely the beginning to understanding what these molecular machines do, and how our bodies really work.

• A cult.
• The deep roots of fascism in the American Right.
• We are at a horrifying inflection point in foreign policy.
• Instead of subsidizing oil and gas, the industry should be charged for damages.
• Are we ready for first contact?

A New Form of Life is Discovered

An extremely short RNA is infectious and prevalent in the human microbiome.

While the last century might be called the DNA century, at least for molecular biology, the current century might be called that of RNA. A blizzard of new RNA types and potentials have been discovered in the normal eukaryotic milieu, including miRNA, eRNA, lincRNA. An RNA virus caused a pandemic, which was remedied by an RNA vaccine. Nobel prizes have been handed out in these fields, and we are also increasingly aware that RNA lies at the origin of life itself, as the first genetic and catalytic mechanism.

One of these Nobel prize winners recently undertook a hunt for small RNAs that might be lurking in the human microbiome- the soup of bacteria, fungi, and all the combined products that cover our surfaces, inside and out. What they found was astonishing- an RNA of merely 1164 nucleotides, which folds up into a rigid, linear rod, which they call "obelisks". This is not a product of the host genome, nor of any other known organism, but is rather some kind of extremely minimal pathogen that, like a transposon or self-splicing intron, is entirely nucleic-acid based. And the more they hunted, the more they found, ultimately finding thousands of obelisk-like entities hidden in the many databases of the world drawn from various environmental and microbiome samples. There is some precedent for this kind of structure, in the form of hepatitis D. This "viroid" of only 1682 nucleotides is a parasite of hepatitis B virus, depending on that virus for key replication functions. While normal viruses (like hepatitis B) encode many key functions of their own, like envelope proteins, genome packaging proteins, and replication enzymes, viroids tend to not encode anything, though hepatitis D does encode one antigenic protein, which exacerbates hepatitis B infections.

The obelisk RNA viroid-like species appear to encode one or two proteins, and possibly a ribozyme as well. The functions of all these are as yet unknown, but necessarily the RNAs rely entirely some host cell (currently unknown) functions to do their thing, such as the RNA polymerase to create copies of itself. Unknown also is whether they are dependent on other viruses, or only on cells for their propagation. Being just discovered, the researchers can do a great deal of bioinformatics, such as predicting the structure of the encoded protein, and the structure of the RNA genome. But key biology, like how they interact with host cells, what functions the host provides, and how they replicate, not to mention possible pathogenic consequences, remain unknown.

The highly self-complementary structure of one obelisk RNA sequence, leading to its identification and naming. In green is one reading frame, which codes for the main protein, of unknown function.

The curious thing about these new obelisk viroid-like RNAs is that, while common in human microbiomes, both oral and gut-derived, they are found only in 5-10% of them, not in all samples. This sort of suggests that they may account for some of the variability traceable to microbiomes, such as autoimmune issues, chronic ailments, nutritional variations, even effects on mood, etc.

Once a lot of databases were searched, obelisk RNAs turn up everywhere, even in some bacteria.

This work was done entirely in silico. Not a single wet-lab experiment was performed. It is a testament to the power of having alot of genomes at our disposal, and of modern computational firepower. This lab just had the idea that novel small viroid-like RNAs might exhibit certain types of (circular, self-complementary) structure, which led to this discovery of a novel form of "life". Are these RNAs alive? Certainly not. They are mere molecules and parasites that feed off, and transport themselves between, more fully functional cells. But they are part of the tapestry of life, which itself is wholly molecular, with many amazing emergent properties. Whether these obelisks turn out to have any medical or ecological significance, they are one more example of the lengths (and shorts) to which Darwinian selection has gone in the struggle for existence. 

• Want to become a rabbi?
• Hey, what happened to reading?
• Is hell other people?

Evolutionary Elaboration of mRNA Splicing

An RNA helicase scoots through the spliceosome to advance the process of mRNA splicing. And some other tricks.

In our cells, virtually all mRNAs transcribed from DNA have to go through an editing process to cut out intervening junk called introns. This process is called splicing, and its evolutionary origin, later elaborations, and current mechanism are all quite interesting. Life didn't start with introns, and only eukaryotes have them as a regular feature of their genomes. They appear to have arrived with the bacterium that became our mitochondria, which come from a lineage that has (relatively few of) what are called group II self-splicing introns. These are RNA segments that behave a bit like transposons, being able to jump into DNA, and then reverse-transcribe that segment into a copy of itself in genomic DNA. 

The ur-eukaryote seems to have had an incredibly prolific infection, which left its host genome riddled with these bits of DNA. A key point is that, in group II introns, their splicing out of a transcribed RNA message is auto-catalytic- entirely mediated by their own RNA structure. They are self-propagating parasites, which have, over time in eukaryotes, been tamed to become fertile aspects of our own gene regulation and evolution. For example, introns often fall between protein domains, allowing these relatively compact modules of protein structure to be replicated, moved, and plugged, via rare mutational events, into new settings to contribute new functions to existing or novel proteins.

A map of a group II self-splicing intron. In red are the ends of the host RNA (or DNA) which are to be either jumped into or excised out of. The rest is the structure of the intron, which carries its own catalytic ability to do these reactions. This kind of thing is what appears to have turned into our own splicing and intron/exon systems, since the core catalytic mechanisms, such as the use of lariats and branch points and RNA catalysis, are the same.

Representation of the core spliceosomal reactions in eukaryotes, which result in a free lariat form of the excised intron, and the joined exons, which go off to code for their protein. "SS" stands for splice site. The sequences in red characterize introns.

The mechanism of intron excision in our cells is, at its core, still RNA-based, even though there are now also hundreds of proteins involved in the rather massive machinery of what is now called the spliceosome. It is clear that over evolutionary time, what was originally an unwelcome and shocking invasion of proto-mitochondrial introns into the proto-nuclear host genome has been regulated, speeded up, accessorized, and integrated into our normal method of gene expression. The spliceosome is the result- a huge and dynamic complex that uses key bits descended from the original RNA catalytic components to guide and catalyze the splicing reaction.

Representation of the core splicing reactions, with the key small RNAs added in (U1, U2, U4, U5, U6). These both guide (by direct RNA-RNA hybrid formation) and perform catalysis at the two chemical bond-breaking/reforming steps.

There are three key locations seized upon by the spliceosome. First is the 5 prime splice site- the end of the coding exon and beginning of the intron, typically a "G" nucleoside at the start of the intron. Second is the branch point, an "A" near the end of the intron, which is where the chemistry of splicing begins. And third is the 3 prime splice site- the end of the intron, with another "G" nucleoside, next to the beginning of the next coding exon. While the first two sites are specifically recognized by RNA components of the spliceosome, (U1 at the 5 prime splice site and U2 at the branch site), the 3 prime splice site is simply recognized by scanning for the first "AG" downstream of the branch site.

The first reaction is to bring the branch site and the 5 prime splice site in proximity, such that the branch site A covalently invades the G at that site and displaces it, releasing the exon end and forming a loop (called a lariat, in red above) in the intronic RNA. The second reaction is to bring the 5 prime exon end over to the 3 prime exon end, and similarly prompt and invasion that links them, displacing the intron entirely.

So simple to describe, but not so easy to do. Accuracy is paramount, since the three-codon reading frame of mRNA would be destroyed by even a 1 nucleoside error in splicing. Splicing now gates the export of mRNA from the nucleus, so that only fully and accurately spliced transcripts get out to the ribosomes in the cytoplasm for translation to protein. This gating has been considered by some the very reason that the nucleus exists at all- a way to solve some of the knotty problems that arose in very early eukaryotic evolution when all these introns invaded. 

Another reaction scheme of splicing, showing the key RNA and some other proteins along the way, principally the key helicases that help drive things forward. Note where PRP2/ATP comes into the picture, just as the complex is preparing for the first catalytic step.

Be that as it may, it is clear that the originally RNA-only mechanism changed over time by accreting proteins that each decided they had something useful to add to the process. At the same time, the RNA got separated into several pieces (on independent genes) that could then be carried and precisely manipulated by these helping proteins. The spliceosome now involves five distinct small RNAs and over 200 proteins, which engage in a complex ballet of sequential steps. A special class of these proteins, the helicases, are the subject of a recent paper that provides new structural information. Helicases are proteins that can use the power of ATP to unwind DNA or RNA, or just chug along it. At least eight such proteins participate in splicing. 

Structures from a recent paper, showing how PRP2 (at bottom, in violet) chugs its way along the mRNA intron (blue) into the very heart of the spliceosome complex, partially evicting the SF3B1 protein (green), among others, and prompting many other changes. At top is shown the 19 nucleoside stretch of the mRNA that was traversed, getting close to the branch site "A" in red. 

The paper makes the interesting observation that, structurally, most of the helicases reside on the periphery of the spliceosomal complexes, while the catalytic and guiding RNA are, naturally, at the center. They use a mutant form of one of them, Aquarius, to freeze spliceosomes in a key conformation just before the branch site and 5 prime splice sites are brought together. In combination with a bunch of other structural work by others in this and other labs, they show that one dynamic event is the tracking by a second helicase, PRP2 (violet, above), that brings it from its peripheral position (b, at bottom) along the intronic mRNA (blue strand) into the core of the splicesome near the U2 RNA (c; U2 is not shown here). They show that PRP2 traverses 19 nucleosides (top, a), a rather remarkable trip that forms part of the sequence of events that brings the branch site and 5 prime splice site close to each other.

Further structures, focusing on the catalytic site and RNAs. Note how the branch site (red, "BS-A") is, after the action of the Aquarius helicase, (third panel), brought in tightly close to the 5 prime splice site (green, "5'SS) in the C, or catalytic, complex. The U2 and U6 RNAs then have an easy job of bond-exchanging catalysis.

So it turns out that these helicases appear sometimes to be used as ratchets, that start on the outside of the complex. Once activated by some prior trigger, they pull on a thread in a way that helps to overall process forward. The progression of PRP2 into the spliceosome core evicts a bunch of other proteins and activates the other helicase Aquarius. That protein is likewise positioned perpipherally but is hanging onto another thread of the intronic RNA and helps to further push the branch and 5 prime splice sites together, in a way that finally leads to the desired reaction. Note in the image above that it is the RNAs that occupy the central reaction site- the intron in blue (green), and the U6 and U2 RNAs, which catalyze this first key reaction of splicing.

RNAs are not great catalysts, so it is understandable that, as in the case of translation by the ribosome, a bunch of proteins shoehorned their way into the process (over evolutionary time) in ways that evidently made splicing more accurate and more rapid. Indeed, yeast cells get along without the Aquarius protein at all, though they otherwise have a very similar splicing apparatus, showing that the accretion of proteins on the spliceosome did not end in very early stages of eukaryotic evolution, but continued through the origin of metazoans, and may still be continuing. The added proteins did this through using their talents for precise spatial positioning, and for the use of energy (from ATP) to drive things ahead, if only by intricate conformational ballet rather than direct catalysis.

• "Ron DeSantis should be forced to carry his presidential campaign to term."
• Nones are not nuns.
• Medical errors and AI.
• The worse the better... GOP edition.
• Two minutes hate.

Some Challenges of Biological Modeling

If modeling one small aspect of one cell is this difficult, how much more difficult is it to model whole cells and organisms?

While the biological literature is full of data / knowledge about how cells and organisms work, we remain far from true understanding- the kind of understanding that would allow computer modeling of their processes. This is both a problem of the kind of data, which is largely qualitative and descriptive, and also of amount- that countless processes and enzymes have never had their detailed characteristics evaluated. In the human genome, I would estimate that roughly half its genes have only been described (if at all) in the most rudimentary way, typically by loose analogy to similar ones. And the rest, when studied more closely, present all sorts of other interesting issues that deflect researchers from core data like their enzymatic rate constants and binding constants to other proteins, as might occur under a plethora of different modification, expression, and other regulatory conditions. 

Then how do we get to usable models of cellular activities? Typically, a lot of guessing is involved, to make anything that approaches a computer model. A recent paper offered a novel way to go down this path, which was to ignore all the rate constants and even interactions, and just focus on the measurements we can make more conveniently- whole metabolome assessments. These are experiments where mass spectrometry is used to evaluate the level of all the smaller chemicals in a cell. If such levels are known, perhaps at a few different conditions, then, these authors argue, we can derive models of their mutual regulation- disregarding all the details and just establishing that some sort of feedback system among these metabolic chemicals must exist to keep them at the observed concentrations.

Their experimental subject is a relatively understandable, but by no means simple, system- the management of iron concentrations in yeast cells. Iron is quite toxic, so keeping it at controlled concentrations and in various carefully-constructed complexes is important for any cell. It is used to make heme, which functions not only in hemoglobin, but in several core respiratory enzymes of mitochondria. It also gets placed into iron-sulfur clusters, which are used even more widely, in respiratory enzymes, in the DNA replication, transcription, protein synthesis, and iron assimilation machineries. It is iron's strong and flexible redox chemistry (and its ancient abundance in the rocks and fluids life evolved with) that make it essential as well as dangerous.

Author's model for iron use and regulation in yeast cells. Outside is on left, cytoplasm is blue, vacuole is green, and mitochondrion is yellow. See text below for abbreviations and description. O2 stands for the oxygen  molecule. The various rate constants R refer to the transition between each state or location.

Iron is imported from outside and forms a pool of free iron in the cytoplasm (FC, in the diagram above). From there, it can be stored into membrane-bound vacuoles (F2, F3), or imported to the mitochondria (FM), where it is corporated into iron-sulfur clusters and heme (FS). Some of the mitochondrially assembled iron-sulfur clusters are exported back out to the cytoplasm to be integrated to a variety of proteins there (CIA). This is indeed one of the most essential roles of mitochondria- needed even if metabolic respiration is for some reason not needed (in hypoxic or anaerobic conditions). If there is a dramatic overload of iron, it can build up as rust particles in the mitochondria (MP). And finally, the iron-sulfur complexes contribute to respiration of oxygen in mitochondria, and thus influence the respiration rate of the whole cell.

The task these authors set themselves was to derive a regulatory scheme using only the elements shown above, in combination with known levels of all the metabolites, under the conditions of 1) normal levels of iron, 2) low iron, and 3) a mutant condition- a defect in the yeast gene YFG1, which binds iron inside mitochondria and participates in iron-sulfur cluster assembly. A slew of differential equations later, and selection through millions of possible regulatory circuits, and they come up with the one shown above, where the red lines/arrows indicate positive regulation, and the red lines ending with bars indicate repression. The latter is typically feedback repression, such as of the import of iron, repressed by the amount already in the cell, in the FC pool. 

They show that this model provides accurate control of iron levels at all the various points, with stable behavior, no singularities or wobbling, and the expected responses to the various conditions. In low iron, the vacuole is emptied of iron, and in the mutant case, iron nanoparticles (MP) accumulate in the mitochondrion, due in part to excess amounts of oxygen admitted to the mitochondrial matrix, which in turn is due to defects in metabolic respiration caused by a lack of iron-sulfur clusters. What seemed so simple at the outset does have quite a few wrinkles!

The authors present their best regulatory scheme, selected from among millions, which provides accurate metabolite control in simulation, as shown by key transitions between conditions as shown here, one line per molecular species. See text and image above for abbreviations.

But note that none of this is actually biological. There are no transcription regulators, such as the AFT1/2 proteins known to regulate a large set of iron assimilation genes. There are no enzymes explicitly cited, and no other regulatory mechanisms like protein modifications, protein disposal, etc. Nor does the cytosolic level of iron actually regulate the import machinery- that is done by the level of iron-sulfur clusters in the mitochondria, as sensed by the AFT regulators, among other mechanisms.

Thus it is not all clear what work like this has to offer. It takes the known concentrations of metabolites (which can be ascertained in bulk) to create a toy system that accurately reproduces a very restricted set of variations, limited to what the researchers could assess elsewhere, in lab experiments. It does not inform the biology of what is going on, since it is not based on the biology, and clearly even contravenes it. It does not inform diseases associated with iron metabolism- in this case Friedreich's ataxia which is caused in humans by a gene related to YFH1- because again it is not biologically based. Knowing where some regulatory events might occur in theory, as one could have done almost as well (if not quantitatively!) on a cocktail napkin, is of little help when drugs need to be made against actual enzymes and actual regulators. It is a classic case of looking under the streetlight- working with the data one has, rather than the data one needs to do something useful.

"Like most ODE (ordinary differential equation)-based biochemical models, sufficient kinetic information was unavailable to solve the system rigorously and uniquely, whereas substantial concentration data were available. Relying on concentrations of cellular components increasingly makes sense because such quantitative concentration determinations are becoming increasingly available due to mass-spectrometry-based proteomic and metabolomics studies. In contrast, determining kinetic parameters experimentally for individual biochemical reactions remain an arduous task." ...

"The actual biochemical mechanisms by which gene expression levels are controlled were either too complicated to be employed in autoregulation, or they were unknown. Thus, we decided to augment every regulatable reaction using soft Heaviside functions as surrogate regulatory systems." ...

"We caution that applying the same strategy for selecting viable autoregulatory mechanisms will become increasing difficult computationally as the complexity of models increases."

But the larger point that motivated a review of this paper is the challenge of modeling a system so small as to be almost infinitesimal in the larger scheme of biology. If dedicated modelers, as this laboratory is, dispair of getting the data they need for even such a modest system, (indeed, the mitochondrial iron and sulfur-containing signaling compound that mediates repression of the AFT regulators is still referred to in the literature as "X-S"), then things are bleak indeed for the prospect of modeling higher levels of biology, such as whole cells. Unknowns are unfortunately gaping all over the place. As has been mentioned a few times, molecular biologists tend to think in cartoons, simplifying the relations they deal with to the bare minimum. Getting beyond that is going to take another few quantum leaps in data- the vaunted "omics" revolutions. It will also take better interpolation methods (dare one invoke AI?) that use all the available scraps of biology, not just mathematics, in a Bayesian ratchet that provides iteratively better models. 

• Some technical advances in 2023.
• Stuttering is a problem, but it isn't a sign.
• How religions break down in political orientation.
• Goodbye 2023: Death Lemonade.

How Does Speciation Happen?

Niles Eldredge and the theory of punctuated equilibrium in evolution.

I have been enjoying "Eternal Ephemera", which is an end-of-career memoir/intellectual history from a leading theorist in paleontology and evolution, Niles Eldredge. In this genre, often of epic proportions and scope, the author takes stock of the historical setting of his or her work and tries to put it into the larger context of general intellectual progress, (yes, as pontifically as possible!), with maybe some gestures towards future developments. I wish more researchers would write such personal and deeply researched accounts, of which this one is a classic. It is a book that deserves to be in print and more widely read.

Eldredge's claim to fame is punctuated equilibrium, the theory (or, perhaps better, observation) that evolution occurs much more haltingly than in the majestic gradual progression that Darwin presented in "Origin of Species". This is an observation that comes straight out of the fossil record. And perhaps the major point of the book is that the earliest biologists, even before Darwin, but also including Darwin, knew about this aspect of the fossil record, and were thus led to concepts like catastrophism and "etagen". Only Lamarck had a steadfastly gradualist view of biological change, which Darwin eventually took up, while replacing Lamarck's mechanism of intentional/habitual change with that of natural selection. Eldridge unearths tantalizing and, to him, supremely frustrating, evidence that Darwin was fully aware of the static nature of most fossil series, and even recognized the probable mechanism behind it (speciation in remote, peripheral areas), only to discard it for what must have seemed a clearer, more sweeping theory. But along the way, the actual mechanism of speciation got somewhat lost on the shuffle.

Punctuated equilibrium observes that most species recognized in the fossil record do not gradually turn into their descendents, but are replaced by them. Eldredge's subject of choice is trilobites, which have a long and storied record for almost 300 million years, featuring replacement after replacement, with species averaging a few million years duration each. It is a simple fact, but one that is a bit hard to square with the traditional / Darwinian and even molecular account of evolution. DNA is supposed to act like a "clock", with constant mutational change through time. And natural selection likewise acts everywhere and always... so why the stasis exhibited by species, and why the apparently rapid evolution in between replacements? That is the conundrum of punctuated equilibrium.

There have been lot of trilobites. This comes from a paper about their origin during the Cambrian explosion, arguing that only about 20 million years was enough for their initial speciation (bottom of image).

The equilibrium part, also termed stasis, is seen in the current / recent world as well as in the fossil record. We see species such as horses, bison, and lions that are identical to those drawn in cave paintings. We see fossils of animals like wildebeest that are identical to those living, going back millions of years. And we see unusual species in recent fossils, like saber-toothed cats, that have gone extinct. We do not typically see animals that have transformed over recent geological history from one (morphological) species into another, or really, into anything very different at all. A million years ago, wildebeest seem to have split off a related species, the black wildebeest, and that is about it.

But this stasis is only apparent. Beneath the surface, mutations are constantly happening and piling up in the genome, and selection is relentlessly working to ... do something. But what? This is where the equilibrium part comes in, positing that wide-spread, successful species are so hemmed in by the diversity of ecologies they participate in that they occupy a very narrow adaptive peak, which selection works to keep the species on, resulting in apparent stasis. It is a very dynamic equilibrium. The constant gene flow among all parts of the population that keeps the species marching forward as one gene pool, despite the ecological variability, makes it impossible to adapt to new conditions that do not affect the whole range. Thus, paradoxically, the more successful the species, and the more prominent it is in the fossil record, the less change will be apparent in those fossils over time.

The punctuated part is that these static species in the fossil record eventually disappear and are replaced by other species that are typically similar, but not the same, and do not segue from the original in a gradual way that is visible in the fossil record. No, most species and locations show sudden replacement. How can this be so if evolution by natural selection is true? As above, wide-spread species are limited in what selection can do. Isolated populations, however, are more free to adapt to local conditions. And if one of those local conditions (such as arctic cold) happens to be what later happens to the whole range (such as an ice age), then it is more likely that a peripherally (pre-)adapted population will take over the whole range, than that the resident species adapts with sufficient speed to the new conditions. Range expansion, for the peripheral species, is easier and faster than adaptation, for the wide-ranging originating species.

The punctuated equilibrium proposition came out in the 1970's, and naturally followed theories of speciation by geographic separation that had previously come out (also resurrected from earlier ideas) in the 1930's to 1950's, but which had not made much impression (!) on paleontologists. Paleontologists are always grappling with the difficulties of the record, which is partial, and does not preserve a lot of what we would like to know, like behavior, ecological relationships, and mutational history. But they did come to agree that species stasis is a real thing, not just, as Darwin claimed, an artifact of the incomplete fossil record. Granted- if we had fossils of all the isolated and peripheral locations, which is where speciation would be taking place by this theory, we would see the gradual change and adaptation taking place. So there are gaps in the fossil record, in a way. But as long as we look at the dominant populations, we will rarely see speciation taking place before our eyes, in the fossils.

So what does a molecular biologist have to say about all this? As Darwin insisted early in "Origin", we can learn quite a bit from domesticated animals. It turns out that wild species have a great amount of mostly hidden genetic variation. This is apparent whenever one is domesticated and bred for desired traits. We have bred dogs, for example, to an astonishingly wide variety of traits. At the same time, we have bred them out to very low genetic diversity. Many breeds are saddled with genetic defects that can not be resolved without outbreeding. So we have in essence exchanged the vast hidden genetic diversity of a wild species for great visible diversity in the domesticated species, combined with low genetic diversity.

What this suggests is that wild species have great reservoirs of possible traits that can be selected for the purposes of adaptation under selective conditions. Which suggests that speciation in range edges and isolated environments can be very fast, as the punctuated part of punctuated equilibrium posits. And again, it reinforces the idea that during equilibrium with large populations and ranges, species have plenty of genetic resources to adapt and change, but spend those resources reinforcing / fine tuning their core ecological "franchise", as it were.

In population genetics, it is well known that mutations arise and fix (that is, spread to 100% of the population on both alleles) at the same rate no matter how large the population, in theory. That is to say- bigger populations generate more mutations, but correspondingly hide them better in recessive form (if deleterious) and for neutral mutations, take much longer to allow any individual mutation to drift to either extinction or fixation. Selection against deleterious mutations is more relentless in larger populations, while relaxed selection and higher drift can allow smaller populations to explore wider ranges of adaptive space, perhaps finding globally higher (fitness) peaks than the parent species could find.

Eldredge cites some molecular work that claims that at least twenty percent of sequence change in animal lineages is due specifically to punctuational events of speciation, and not to the gradual background accumulation of mutations. What could explain this? The actual mutation rate is not at issue, (though see here), but the numbers of mutations retained, perhaps due to relaxed purifying selection in small populations, and founder effects and positive selection during the speciation process. This kind of phenomenon also helps to explain why the DNA "clock" mentioned above is not at all regular, but quite variable, making an uneven guide to dating the past.

Humans are another good example. Our species is notoriously low in genetic diversity, compared to most wild species, including chimpanzees. It is evident that our extremely low population numbers (over prehistoric time) have facilitated speciation, (that is, the fixation of variants which might be swamped in bigger populations), which has resulted in a bewildering branching pattern of different hominid forms over the last few million years. That makes fossils hard to find, and speciation hard to pinpoint. But now that we have taken over the planet with a huge population, our bones will be found everywhere, and they will be largely static for the foreseeable future, as a successful, wide-spread species (barring engineered changes). 

I think this all adds up to a reasonably coherent theory that reconciles the rest of biology with the fossil record. However, it remains frustratingly abstract, given the nature of fossils that rarely yield up the branching events whose rich results they record.

• TV in China.
• How now at the Supreme Court?
• Tears are powerful.